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Summary
The osteonecrosis of the jaw is a new emergent disease, sec-
ondary to prolonged use of bisphosphonates. Bisphospho-
nates are a class of drug used in prevention and cure of bone
diseases such as malignancy or bone metabolic diseases. In
this article, we have tried to summarize, for patients taking IV
or oral bisphosphonates-therapy, the most important informa-
tions on the pathogenesis and the risk factors in osteonecro-
sis of the jaw with particular attention about the preventive
policies. 
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Background
In the last four years an increasing number of case reports, let-
ters to editors and reviews have (1-6) described the os-
teonecrosis of the jaw (ONJ) in patients treated with bisphos-
phonates (BIS). The objective of this paper is to focus practical
guidelines and recommendations about ONJ prevention.
Bisphosphonates are used to prevent or to treat osteoporosis,
Paget’s disease of bone and other metabolic bone diseases
(7-9). In patients affected by multiple myeloma and metastatic
bone cancer, BIS are strategic drugs to treat severe hypercal-
cemia, pain and skeletal events (fractures, spinal cord com-
pressions) (10, 12). The most recent nitrogen-containing bis-
phosphonates or aminobisphosphonates have greater potency
and better selectivity of action. Zoledronic acid and
pamidronate have been using intravenous in neoplastic dis-
eases, while oral alendronate, residronate and ibandronate
have been using in rheumatologic patients. These drugs are
powerful inhibitors of bone resorption. This effect gives rise to
the blocking osteoclastic activity due to the cell apoptosis (11),
and by inducing osteoblasts to cause an osteoclast-inhibiting
factor (13). Moreover, BIS may induce a tumor cell apoptosis
and also antiangiogenetic effect (14, 15).
ONJ related to BIS is also named BRONJ, BRON, BON, avas-
cular necrosis (1, 16, 17).
ONJ is clinically characterized by an area of yellow-white ex-
posed bone, persisting for more than 8 weeks, associated with
current or previous treatment with BIS and without history of ra-
diation therapy of the jaw (16). The ONJ could also present as
non healing extraction socket, gingival swelling or purulent dis-
charge. Often patient may remain asymptomatic until sites be-
come infected (4, 18).
At the moment, ONJ’s treatment is a great challenge and many
problems remain unsolved. A lot of reports have shown a negli-
gible response to the different attempt of treatment (surgical
therapy, local or systemic antimicrobial therapy and hyperbaric
therapy). However it seems clear that the primary goal, in the
treatment of the ONJ, is to eliminate pain, controlling sec-
ondary infections of the soft and hard tissues and minimize the
progression or occurrence of bone necrosis (4, 5). 
Pathogenesis and risk factors
In the management of ONJ is essential to evaluate the risk fac-
tors for developing effective preventive measures.
Since the first paper published in 2003 (1), a lot of reports have
contributed to clarify our understanding on the pathogenesis of
the ONJ induced by BIS. From those works have been elabo-
rated the requirement for the preventive strategy.
Pathogenetic hypothesis: The mechanisms by which BIS may
cause ONJ are not completely explained.
The inhibition of osteoclast-mediated resorption of bone seems
to be a possible pathogenetic mechanism. The suppression of
bone remodelling and an increase of the mineralization, lead to
formation of brittle bone (19, 20). The inhibition of bone remodel-
ling could produce an accumulation of microfractures in the jaw
as effect of the daily mastication. In addition, to the anti-angio-
genetic  effect of BIS it could reduce blood flow and cause os-
seous hypoxia (5). Moreover, the concomitant compromised
vascular supply associated with superinfectious of hard and soft
tissues may play an important part to cause ONJ.
Recently, a new hypotesis has been proposed by Ardine and
Berruti. It is common knowledge that patients with cancer pre-
sented, during only first month of treatment with BIS, an in-
crease of the PTH levels. In Berruti’s study, patients with
metastatic breast cancer developing ONJ, have a clear persis-
tence of relative hypocalcemia and secondary hyperparathy-
roidism at the time preceding this event. Subsequently obstacu-
lated bone repair may contribute to genesis of ONJ (21). 
Risk factors
The most important predisposing factors are: 
a) the type of BIS, the total dose and lenght of treatment. The
risk is substantially higher in patients taking zoledronic acid
than pamidronate, because the former is much potent and
with a longer half-life. Durie et al., reported an incidence of
ONJ 10% of the patients receiving zoledronic acid, com-
pared with 4% receiving pamidronate, at 36 months censure
of data (22). Bamias et al., described an increased inci-
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dence of ONJ correlated with – increasing – the number of
the BIS infusions and with the exposition (23, 24);
b) recent dental surgical procedures are present in 60% of all
cases, respect to the cases of spontaneous osteonecrosis
(4, 25, 27);
c) patient older age and sex female are more frequently asso-
ciated to ONJ (25, 26) in myeloma; 
d) the highest incidence of ONJ seemed in myeloma patients
(10%), respect to breast cancer (3%) and prostate cancer
(7%) (23) (Table I).
There are others conditions  usually related to osteonecrosis,
which are considered as furter risk factors and therefore evalu-
tated and scheduled. In brief they could be indicate as general
or local risk. However, further study are required to determine
their importance.
Table I - Predisposing factors to ONJ.
– Type, total dose and length of treatment with bisphosphonates
– Prior history of dental procedures or oral infections
– Older age
– Female sex
– Type of malignancy
ONJ: osteonecrosis of the jaw.
General risk factors are: neoplasia, chemotherapy, corticos-
teroids, diabetes, smoking, overindulgence in alcohol, old age,
female sex, anemia, coagulopathies (16, 18). In multiple
myeloma doesn’t appear to be an additional risk of ONJ in as-
sociation to the treatment with thalidomide or corticosteroid
(22, 23, 28).
Only Zervas and colleagues described an increased risk of
ONJ 2-4 fold in patients treated with thalidomide (29).
At this moment,  further studies are necessary to evaluate the
potential relationship between ONJ BIS associated in patients
taking others anti-angiogenetic drugs – such as Bortezomib –
or aromatase inhibitors used in adjuvant cancer therapy.
Local risk factors are: locoregional radiotherapy, dental proce-
dures, poor oral hygiene, dental or periodontal infections, local
trauma and edentoulus region (16, 30).
Guidelines for prevention 
Considering that, at the moment, many questions on ONJ re-
maining open it doesn’t seem easy to provide definitive recom-
mendations on the more useful preventive strategies. To make
easier, it could try dividing the patients into two groups, those
treated with intravenous BIS for malignancy and those taking
oral BIS for osteoporosis and other rheumatologic diseases.
Intravenous BIS (Table II) – Those patients have high risk of
ONJ. The incidence of ONJ raising 6-11% in myeloma and 3-
6% in neoplastic disease (22, 23, 28).
On June 2004, a panel of expert, developed a series of recom-
mendations for the diagnosis prevention and treatment of the
ONJ associated to the BIS in cancer patients (30). This “white
paper” was distribuited during ASCO meeting and subsequent-
ly was submitted a two reviews on January and December
2006 respectively (18, 31).
Initially the recommendations developed by the panel were ap-
plied to specific two subsets of patients with neoplastic diseases.
The former (group 1) involved patients before beginning BIS
therapy. The latter (group 2) regarded patients already taking
BIS drugs. Also Woo et colleagues have divided patients in two
similar group. In the first group, are added patients who have
less than 3 months of drug therapy while in the second group the
patients with more than 3 months of therapy (6). In an other pa-
per Ruggiero described a common pathway, with few differences
between patients which haven’t urgency to begin therapy and
patients during therapy (31). It would like to submit every patient
to oral evaluation and to a jaw X-ray, to detect incidental dental
and periodontal disease (4). Oral x-ray is conventionally used as
a first step to detect a characteristic imaging features of os-
teonecrosis. Subsequently when ONJ is suspected a CT scan is
useful to display ostheolytic lesions with the involvement of corti-
cal bone whereas MRI is very important to determine the lesion
extension in soft tissues. 
PET and 99Tc – MPD 3 – phase bone scan scintigraphy are
described such as very sensitive investigation to detect sub-
clinical osteonecrosis (32, 33).
In case of documented problems is suggested to remove ab-
scesses and cure all sites that seemed at high risk of infection.
Patients should be instructed to avoid any aggressive dental
procedure and to prefer conservative dental therapy (endodon-
tic therapy) if possible. Only if metastatic disease is suspected,
tissue biopsies are performed, associated with microbial cul-
tures (6, 31).
The teeth with a poor prognosis should be extract prior to start-
ing BIS-therapy and it is important to allow a complete tissues
healing. Several authors (16, 34) have recommended in pa-
tients, taking therapy, to suspend BIS, from 1 to 3 months be-
fore the invasive dental procedure and resuming when oral
healing is complete. The stop of the BIS therapy is fundamen-
tal to remove the antiangiogenic effect upon the soft tissues
around the periosteum of the jaw; in this way could be better
the mechanism of tissue repair (6, 31). Modification or cessa-
tion of BIS therapy should be done in the consultation with the
treating physician and the patient.
Those patients should not be considered as candidates for
dental implants.
Periodic examination of full dentures is recommended. The pa-
tients should be educated about the importance of maintaining
good oral hygiene, without soft tissue injuries, and a prompt
surveillance of dental care. Patients must be informed about
ONJ, including an explanation of its signs, symptoms and clini-
cal features. Prophylactic antibiotic therapy before of the non
invasive dental care is not required but is recommended for all
invasive dental procedure and in patients with risk of bac-
teremia  (venous central cateter carrier). It is important to per-
form twice year a professional dental cleanig. A brief visual
Table II - Guidelines for patients taking intravenous Bisphospho-
nates.
– Perform dental clinical evaluation and panoramic jaw radiograph
– Remove abscesses and other high risk infection sites 
– Avoid tooth extraction and dental implants
– Prefer conservative therapy (eg. endodontic therapy)
– Check removable dentures
– Maximize good oral hygiene
– Show to patients the signs, symptoms, and clinical feactures of
ONJ
– Provide regulary scheduled hard and soft oral tissue assessments
– Develop a close collaboration between patient,oncologist,dentist
and oral surgeon
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evaluation by oncologist at every follow-up visit. The frequency
of checks should be every 3 or 4 months, depending on the
concomitant risk factors.
A close collaboration among patient, oncologist/haematologist,
dentist and oral surgeon is fundamental for the prevention of
ONJ and for a quick identification of the problems. Recently, in
multiple myeloma Lacy and colleagues recommended to dis-
continue BIS after 2 years of therapy, in the patients in remis-
sions or plateau phases, and to reduce the frequency of BIS
therapy every 3 months in patients with active disease. More-
over for newly diagnosed patients the use of pamidronate in-
stead of zoledronic acid is suggested (34).
Oral BIS: (Table III) Oral BIS are used in osteopenia, in osteo-
porosis related to menopause, inflammatory bowel disease,
primary biliary cirrhosis, steroid therapy, Paget’s bone disease,
osteogenesis imperfecta of childhood and other rheumatologic
diseases (7-9, 16, 17). These patients have a potential, but
very low risk of ONJ. Among patients who have received oral
therapy for osteoporosis 50 cases of ONJ have been reported
(6) and 5 cases in Paget’s disease of bone (17).
In patients taking alendronate the incidence of ONJ has been
estimated to occur in approximately 0,7/100000 persons/year
exposure. Few cases was described in patients treated with
ibandronate (12 cases) and residronate (1 case) (17). Up to
day, the estimate of incidence of osteonecrosis is based on in-
complete data and prospective studies are needed.
Oral BIS have a minor bio-availability for the incorporation into
the bone matrix and this may account for the low number of
cases of ONJ (36, 37). 
Though patients treated with oral BIS have a low risk of ONJ, it is
necessary to be aware about the necessity of a prevention pro-
gramme. For this reason would be useful before to start oral BIS-
therapy that the physician collect a brief history for systemic or lo-
cal risk factors and also submits to oral evaluation all patients.
Afterwards, periodic control of oral care should be scheduled,
to reduce dental and periodontal infections. Each patient must
be addressed in developing oral care. The risk and benefit pro-
file for each patient should be considered before and during
therapy (38).
Initially patients taking oral BIS have the same preventive like
the patients who must start BIS- IV therapy (6).
In 2006 a panel of expert developed clinical guidelines for the
prevention and dental management of patients receiving oral
BIS (16, 17). As pictured from this study, the risk of developing
ONJ with oral BIS is increased if the therapy exceeded three
years or when it is associated with steroids or in elderly pa-
tients (16).
In these guidelines patients are divided in three groups. 
Group 1: individuals who take oral therapy for less than three
years and haven’t any further clinical risk factors. 
Group 2: individuals who take oral therapy for less three years
and had also taken corticosteroids concomitantly. 
Group 3 patients who take therapy for more than three years
with or without concomitant steroids. 
In patients of group 1, routine dental treatment and surgical jaw
procedures should be not modified. In both group 2 and 3 the
endodontic therapy is preferred to tooth extraction and invasive
periodontal procedures. If the disease situation for which the
BIS therapy is assumed is getting well, the authors of the paper
encourage the discontinuation of the oral therapy for at least
three months before oral surgery.They suggest to start again
BIS therapy only when osseous healing has occurred. Patients
with implants are regulary monitored to avoid peri-implantitis.
Before the placement of implants, dentist and patient should be
discuss the risks and benefit of the treatment. In any case it
would be better obtaining a written consent from the patient.
Patients in BIS therapy for post-menopausal osteoporosis
should be considered for an alternative therapy: estrogens,
raloxifene, strontium ranelate, teriparatide or clodronate. Clo-
dronate is BIS of first-generation that doesn’t seem associated
to ONJ (39, 40). In patients treated with oral BIS for five or
more years, a “drug holiday”, a discontinuation of BIS therapy
until one year have been recommended. These recommenda-
tions are based on the hypotesis that this procedure may miti-
gate the risk of ONJ.
Conclusions
ONJ is a serious complication of long-term BIS therapy. These
drugs are effective in the treatment of hypercalcemia, osteolytic
lesion in myeloma,  bone metastatic cancer and to prevent and
cure osteoporosis and other metabolic bone diseases. Many
questions are yet unanswered. Prospective and retrospective
case-control studies are also needed to determine which addi-
tional risk factors may predispose the patients to the develop-
ment of ONJ. Let’s hope that in the future might be created a
national registry to allow systematic study of cases of ONJ. In
that prospective, the basic research should have the aim to
better explain pathophisiology of ONJ and should be made
easier to determine the best approach to perform a tailored
pathway in patients treated with BIS.
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